Emgality 300 mg: First and only calcitonin gene-related peptide (CGRP) antibody proven to treat patients with episodic cluster headache1,2

For your patients with episodic cluster headache,

    Get your eligible patients started. Download Savings Cardsc

    cGovernmental beneficiaries excluded; terms and conditions apply.

    References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0120. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0093.

    INDICATIONS

    Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

    • Preventive treatment of migraine
    • Treatment of episodic cluster headache

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATIONS
    Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

    ADVERSE REACTIONS
    The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

    Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

    GZ HCP ISI 10DEC2019